Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Timothy, Burn"'
Autor:
Shirin Emtenani, Maike M. Holtsche, Richard Stahlkopf, Daniel L. Seiler, Timothy Burn, Huiqing Liu, Melissa Parker, Kaan Yilmaz, Hasan O. Dikmen, Markus Huber Lang, Christian D. Sadik, Christian M. Karsten, Nina van Beek, Ralf J. Ludwig, Jörg Köhl, Enno Schmidt
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Bullous pemphigoid (BP), the by far most frequent autoimmune subepidermal blistering disorder (AIBD), is characterized by the deposition of autoantibodies against BP180 (type XVII collagen; Col17) and BP230 as well as complement components at the der
Externí odkaz:
https://doaj.org/article/e8cb36281fae4c35a6c0ba273e085086
Autor:
Qian Wang, Sybil O'Connor, Alan Roberts, Brian W. Metcalf, Leslie Hall, Maxim Soloviev, Michael Hansbury, Greg Hollis, Xin He, Matthew C. Stubbs, Niu Shin, Wenqing Yao, Kamna Katiyar, Phillip C.C. Liu, Kathy Wang, Sharon Diamond, Brent Douty, Gengjie Yang, Dana Shuey, Maryanne B. Covington, Paul Collier, Mingming Gao, Patricia Feldman, Peggy Scherle, Timothy Burn, Andrew P. Combs, Yun-Long Li, Lynn Leffet, Robert C. Newton, Paul Waeltz, Holly Koblish, Jin Lu, Swamy Yeleswaram, Yanlong Li, Reid Huber, Robert Collins, Eddy W. Yue
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:211-222
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)δ inhibitors in B-cell malignancies is hampered by hepatotoxicity, requiring dose reduction, treatment interruption, and/or discontinuation of therapy. In addition, potential molec
Autor:
Reid Huber, Maryanne Covington, Xin He, Paul Waeltz, Valerie Dostalik, Yanlong Li, Nina Zolotarjova, Chu-Biao Xue, Matthew C. Stubbs, Jun Li, Huiqing Liu, Peggy Scherle, Timothy Burn, Sharon Diamond, Thomas Maduskuie, Wenqing Yao, Padmaja Polam, Richard B. Sparks, Christine Gardiner, Xuesong Mike Liu, Robert Collins, Nikoo Falahatpisheh, Andrew P. Combs, Phillip Liu, Margaret Favata, Gregory Hollis, Richard Wynn, Swamy Yeleswaram, Bruce Ruggeri, Alla Volgina, Ravi Kumar Jalluri, Pramod Thekkat, Darlise DiMatteo, Patricia Feldman, Mark Rupar, Xiaoming Wen
Publikováno v:
Clinical Cancer Research. 25:300-311
Purpose: Bromodomain and extraterminal domain (BET) proteins regulate the expression of many cancer-associated genes and pathways; BET inhibitors have demonstrated activity in diverse models of hematologic and solid tumors. We report the preclinical
Autor:
Gretchen Johnston, Scott W. Hiebert, Michael R. Savona, Jing Wang, Matthew C. Stubbs, Pankaj Acharya, Qi Liu, Timothy Burn, Maria Pia Arrate, Haley E. Ramsey, Shilpa Sampathi, Kristy R. Stengel
Publikováno v:
Gene
Drugs targeting chromatin-modifying enzymes have entered clinical trials for myeloid malignancies, including INCB059872, a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1). While initial studies of LSD1 inhibitors suggested th
Autor:
Niu, Shin, Matthew, Stubbs, Holly, Koblish, Eddy W, Yue, Maxim, Soloviev, Brent, Douty, Kathy He, Wang, Qian, Wang, Mingming, Gao, Patricia, Feldman, Gengjie, Yang, Leslie, Hall, Michael, Hansbury, Sybil, O'Connor, Lynn, Leffet, Robert, Collins, Kamna, Katiyar, Xin, He, Paul, Waeltz, Paul, Collier, Jin, Lu, Yun-Long, Li, Yanlong, Li, Phillip C C, Liu, Timothy, Burn, Maryanne, Covington, Sharon, Diamond, Dana, Shuey, Alan, Roberts, Swamy, Yeleswaram, Greg, Hollis, Brian, Metcalf, Wenqing, Yao, Reid, Huber, Andrew, Combs, Robert, Newton, Peggy, Scherle
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 374(1)
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)
Autor:
Peggy Scherle, Timothy Burn, Sharon Diamond, Ronald M. Klabe, Wenqing Yao, Liangxing Wu, Reid Huber, Darlise DiMatteo, Alla Volgina, Kevin Bowman, Holly Koblish, Bruce Ruggeri, Xin He, Krista A. Burke, Yue Zhang, Swamy Yeleswaram, Christine Gardiner, Richard Wynn, Maxim Soloviev, Maryanne B. Covington, Gregory Hollis, Mark Rupar, Xiaoming Wen, Patricia Feldman, Michael Hansbury, Phillip C.C. Liu, Paul Collier
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231877 (2020)
PLoS ONE
PLoS ONE
Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been
Publikováno v:
Journal of Investigative Dermatology. 141:S157
Autor:
Sharon Diamond, Kamna Katiyar, Qian Wang, Andrew P. Combs, Holly Koblish, Gengjie Yang, Jordan S. Fridman, Maryanne B. Covington, Gregory Hollis, Yanlong Li, Jun Li, Swamy Yeleswaram, Xin He, Reid Huber, Yun-Long Li, Lynn Leffet, Mark Rupar, Kathy Wang, Dana Shuey, Wenqing Yao, Leslie Hall, Maxim Soloviev, Kevin Bowman, Robert C. Newton, Mike Liu, Margaret F. Favata, Peggy Scherle, Timothy Burn, Kris Vaddi, Beth Rumberger, Song Mei, Niu Shin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 364:120-130
Phosphatidylinositol 3-kinase delta (PI3Kδ) is a critical signaling molecule in B cells and is considered a target for development of therapies against various B cell malignancies. INCB040093 is a novel PI3Kδ small-molecule inhibitor and has demons
Autor:
Srdan Verstovsek, Timothy Burn, Jean-Jacques Kiladjian, Ahmad Naim, Alessandro M. Vannucchi, Brian Gadbaw, Mahtab Marker, Martin Griesshammer, Paola Guglielmelli, Dilan Paranagama
Publikováno v:
Annals of Hematology
In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reduct
Autor:
Brian M. Glass, Padmaja Polam, Tom Emm, Kevin Bowman, Jordan S. Fridman, Holly Koblish, Richard Wynn, Michael Hansbury, Yanlong Li, Eddy W. Yue, Brian Metcalf, Michael J. Bower, Min Wei, Richard B. Sparks, Peggy Scherle, Xiangdong Liu, Andrew P. Combs, Timothy Burn, Dilip P. Modi, Brian Wayland, Qian Wang, Lynn Leffet, Brent Douty, Wenyu Zhu, Amy Takvorian, Joseph Glenn
Publikováno v:
ACS Medicinal Chemistry Letters
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat). The molecular structure of INCB24360 contains several previously unknown or underutilized functional groups in drug